ArticleJournal of inflammation research2025
Potential Targets and Mechanisms of Saikosaponin D in Psoriasis: A Bioinformatic and Experimental Study on Oxidative Stress.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Network Pharmacology and Animal Experimental Validation on the Therapeutic Mechanisms ofClinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to explore the potential therapeutic effect of Saikosaponin D (SSD) on psoriasis and elucidate its underlying mechanisms, focusing on oxidative stress modulation and immune regulation. Methods: Network pharmacology, machine learning (LASSO, SVM-RFE, Random Forest), and molecular dynamics identified Saikosaponin D's core targets (STAT3, CCNB1) in psoriasis. Differential gene analysis (GEO datasets GSE6710, GSE50790, GSE14905), WGCNA, and PPI networks screened Saikosaponin D-psoriasis-oxidative stress intersecting genes. In vivo validation employed an imiquimod-induced psoriasis mice model with Saikosaponin D (2 mg/kg/day). Histology, qPCR, Western blot, and immune infiltration (CIBERSORT) assessed SAIKOSAPONIN D's effects on inflammation, JAK2/STAT3 signaling, and oxidative stress markers (GPX4, SLC7A11). Results: Saikosaponin D markedly alleviated psoriasis-like symptoms, diminishing epidermal thickness and keratinocyte proliferation, accompanied by reduced Ki67 expression. Bioinformatics investigation revealed 25 intersecting genes, with STAT3 and CCNB1 identified as principal targets. Molecular docking revealed that Saikosaponin D consistently binds to STAT3 and CCNB1, with binding energies of -8.3 and -9.0 kcal/mol, respectively. Saikosaponin D suppressed JAK2/STAT3 phosphorylation, leading to the downregulation of IL-1, IL-6, and TNF-α expression. Saikosaponin D enhanced GPX4 expression and reduced SLC7A11 levels, restoring oxidative equilibrium. Moreover, Saikosaponin D regulated immune infiltration by reducing M1 macrophages and augmenting Tregs, hence enhancing the psoriatic immune microenvironment. Conclusion: Saikosaponin D suppresses psoriasis by dual-targeting STAT3/CCNB1, disrupting JAK2/STAT3 signaling and oxidative stress. This study provides new insights into the mechanism of Saikosaponin D in psoriasis, offering a promising multi-pathway therapeutic candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.